Understanding the Current Paradigm and New Approaches in the Care of Patients with Cancer

A Complimentary NCPD Hybrid Symposium Series Held During the 50<sup>th</sup> Annual ONS Congress

**Ovarian Cancer** Friday, April 11, 2025 12:15 PM - 1:45 PM Faculty **Courtney Arn, CNP** Jennifer Filipi, MSN, NP David M O'Malley, MD Shannon N Westin, MD, MPH, FASCO, FACOG **Moderator** Neil Love, MD



# Faculty



**Courtney Arn, CNP** The James Cancer Hospital and Solove Research Institute The Ohio State University Columbus, Ohio



David M O'Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics
and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James
Comprehensive Cancer Center
Columbus, Ohio



#### Jennifer Filipi, MSN, NP

Department of Gynecologic Oncology Massachusetts General Hospital Cancer Center Boston, Massachusetts



Shannon N Westin, MD, MPH, FASCO, FACOG Professor Medical Director, Gynecologic Oncology Center Director, Early Drug Development Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston, Texas



# Ms Arn — Disclosures

Speakers Bureaus	AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, ImmunoGen Inc, Merck, Pfizer Inc
------------------	---



# Ms Filipi — Disclosures

No relevant conflicts of interest to disclose.



# **Dr O'Malley — Disclosures**

Advisory Committees	AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc,
and Consulting	GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology
Agreements	Inc, Sutro Biopharma, Verastem Inc
Contracted Research	AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals
Nonrelevant Financial	Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer
Relationships	Institute, NRG Oncology, RTOG Foundation, SWOG



# **Dr Westin — Disclosures**

Consulting Agreements	AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio
Contracted Research (to Institution)	AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Clovis Oncology, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Zentalis Pharmaceuticals



# **Commercial Support**

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Merck.

# Research To Practice NCPD Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.



This educational activity contains discussion of non-FDA-approved uses of agents and regimens. Please refer to official prescribing information for each product for approved indications.



# **Clinicians in the Meeting Room**

#### Networked iPads are available.



Review Program Slides: Tap the Program Slides button to review speaker presentations and other program content.



Answer Survey Questions: Complete the pre- and postmeeting surveys. Survey questions will be discussed throughout the meeting.



Ask a Question: Tap Ask a Question to submit a challenging case or question for discussion. We will aim to address as many questions as possible during the program.

For assistance, please raise your hand. Devices will be collected at the conclusion of the activity.



# **Clinicians Attending via Zoom**

|--|

Review Program Slides: A link to the program slides will be posted in the chat room at the start of the program.



Answer Survey Questions: Complete the pre- and postmeeting surveys. Survey questions will be discussed throughout the meeting.




Ask a Question: Submit a challenging case or question for discussion using the Zoom chat room.



Get NCPD Credit: An NCPD credit link will be provided in the chat room at the conclusion of the program.



# **Clinicians, Please Complete the Pre- and Postmeeting Surveys**





# **About the Enduring Program**

- The live meeting is being video and audio recorded.
- The proceedings from today will be edited and developed into an enduring web-based program. An email will be sent to all attendees when the activity is available.



 To learn more about our education programs, visit our website, <u>www.ResearchToPractice.com</u>



# ONCOLOGY NURSING UPDATE WITH DR NEIL LOVE

Bispecific Antibodies in Lymphoma Part 1 — An Interview with Ms Robin Klebig for Oncology Nurses




MS ROBIN KLEBIG









Ms Robin Klebig — Bispecific Antibodie Oncology Today with Dr Neil Love —

(30)

(15)

# "Understanding the Current Paradigm and New Approaches" Seventeenth Annual RTP-ONS NCPD Symposium Series

Wednesday April 9	Antibody-Drug Conjugates 11:15 AM - 12:45 PM MT
	Hormone Receptor-Positive Breast Cancer 6:00 PM - 8:00 PM MT
Thursday April 10	Chronic Myeloid Leukemia 6:00 AM - 7:30 AM MT
	Prostate Cancer 12:15 PM - 1:45 PM MT
	Chronic Lymphocytic Leukemia 6:00 PM – 7:30 PM MT
Friday April 11	<b>Bispecific T-Cell Engagers for Small Cell Lung Cancer</b> 6:00 AM - 7:30 AM MT
	Ovarian Cancer 12:15 PM - 1:45 PM MT
	Pancreatic Cancer 6:00 PM - 7:30 PM MT
Saturday April 12	Endometrial Cancer 6:00 AM - 7:30 AM MT
	Gastroesophageal Cancers 12:15 PM - 1:45 PM MT
	Non-Hodgkin Lymphoma 6:00 PM - 7:30 PM MT



#### Understanding the Current Paradigm and New Approaches RTP Faculty at ONS 2025



RTP RESEARCH TO PRACTICE Understanding the Current Paradigm and New Approaches in the Care of Patients with Cancer

A Complimentary NCPD Hybrid Symposium Series Held During the 50<sup>th</sup> Annual ONS Congress

**Ovarian Cancer** Friday, April 11, 2025 12:15 PM - 1:45 PM Faculty **Courtney Arn, CNP** Jennifer Filipi, MSN, NP David M O'Malley, MD Shannon N Westin, MD, MPH, FASCO, FACOG **Moderator** Neil Love, MD



# Agenda

**Introduction:** Overview of Ovarian Cancer (OC) Management

**Module 1:** Genetic Testing for Newly Diagnosed Advanced OC

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

**Module 3:** Other Available and Investigational Novel Strategies for OC

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment



# Agenda

Introduction: Overview of Ovarian Cancer (OC) Management

**Module 1:** Genetic Testing for Newly Diagnosed Advanced OC

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

**Module 3:** Other Available and Investigational Novel Strategies for OC

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment



# CASE STUDY

- Patient with history of IIIC high grade serous ovarian cancer
- Initially presented with abdominal pain and was found to have bilateral pelvic masses and elevated CA-125
- Underwent debulking surgery and 6 cycles of carboplatin/paclitaxel
- Germline BRCA2 mutation
- Counseled on parp inhibitors immediately
- Completed 2 years of maintenance Olaparib 300 mg BID in 2022
- Tolerated treatment well, currently has no evidence of disease
- Biopsychosocial Issues: Adopted, good family support, history of stroke

#### Courtesy of Courtney Arn, CNP

# Agenda

### **Introduction:** Overview of Ovarian Cancer (OC) Management

Module 1: Genetic Testing for Newly Diagnosed Advanced OC

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

**Module 3:** Other Available and Investigational Novel Strategies for OC

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment



# Overview of Ovarian Cancer Management; Importance of Genetic Testing in Newly Diagnosed Advanced OC

Shannon N. Westin, MD, MPH


Professor

Department of Gynecologic Oncology and Reproductive Medicine

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center


Making Cancer History®

# **Typical Course of Advanced Ovarian Cancer**



Ledermann JA, et al. Ann Oncol. 2013, Pignata S, et al. Ann Oncol. 2017; du Bois A, et al. Cancer 2009, Wilson MK, et al. Ann Oncol. 2017

# **Germline vs Somatic Mutations**



Germline mutations are inherited and found in all cells – they are stable and do not change. Somatic mutations are not inherited and are found within the tumor – they can change over time. Both can impact cancer risk

# Which genes are associated with ovarian cancer risk and who should we test?

- BRCA1 and BRCA2
- RAD51C, RAD51D, BRIP1, PALB2
- Lynch syndrome (*MLH1, MSH2, MSH6, PMS2, EPCAM*)

Leading oncology societies recommend testing all women with ovarian cancer

#### NCCN

Genetic counseling and testing should be considered in women with a history of ovarian carcinoma, fallopian tube cancer, or primary peritoneal cancer<sup>1</sup>

#### SGO

Women diagnosed with epithelial ovarian, tubal, and peritoneal cancers should receive genetic counseling and be offered genetic testing, even in the absence of family history<sup>2</sup>

#### ASCO


Genetic counseling and testing should be considered in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer even in the absence of family history<sup>3</sup>

#### ESMO

Patients with high-grade tumours should be tested for a germline BRCA mutation. Consideration should be given to testing tumours for a somatic BRCA mutation<sup>4</sup>

# **Common Aberrations in Ovarian Cancer**

These defects can be identified using different clinical and molecular biomarkers




# **Clinical Implications:**

Approximately 50% High Grade Epithelial Ovarian Cancers Characterized by HRD Is this targetable in recurrent epithelial ovarian cancer?

Konstantinopoulos PA, et al. Cancer Discov. 2015

# **Importance of Cascade Testing**



# MDAnderson Universal Genetic Testing: Missed Opportunities

Making Cancer History®

- Meta-analysis (n=35 studies)
- 39% Referral to genetic counseling
- 30% Completion of genetic testing

#### Table 1

Pooled proportions of referral to genetic counseling and completion of genetic testing by race and insurance status.


	% Referred to counseling (95% CI)	% Completed genetic testing (95% CI)
Race		
White	43% (26-62%)	40% (25-57%)
Black	24% (13-42%)	26% (17-38%
Asian	23% (2–83%)	14% (2–51%)
Insurance status		
Private insurance	39% (26-54%)	47% (30-64%)
Medicare/Medicaid	27% (18-38%)	26% (16-40%)
Uninsured	24% (13–51%)	23% (18-28%)

Lin et al Gyn Onc 2021




Making Cancer History\*

# **New Testing Paradigm**




# **Molecular Testing in Ovarian Cancer: Which Tests Should Be Used?**



#### Homologous recombination status is determined by genomic instability score:

- HR-deficient tumors: tissue GIS ≥42 or a BRCA mutation
- HR-proficient tumors: tissue GIS <42</p>
- HR not determined



tumors: LOH  $\geq 16$ 

 HRD genes, including BRCA1 and BRCA2

#### Tempus®


- BRCA LOH and somatic genome-wide LOH
- HRD genes, including BRCA1 and BRCA2

<sup>a</sup> Tests have not been compared head-to-head. Paired with development of respective drugs.


#### National Comprehensive Cancer Network®

#### NCCN Guidelines Version 1.2025 Epithelial Ovarian Cancer/Fallopian Tube Cancer/ Primary Peritoneal Cancer

NCCN Guidelines Index Table of Contents Discussion



# First-Line Chemotherapy Standard of Care: Carboplatin, Paclitaxel & Bevacizumab + Maintenance



Burger RA et al. N Engl J Med. 2011; Perren TJ et al. N Engl J Med. 2011

# **Roundtable Discussion**



# Agenda

**Introduction:** Overview of Ovarian Cancer (OC) Management

**Module 1:** Genetic Testing for Newly Diagnosed Advanced OC

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

**Module 3:** Other Available and Investigational Novel Strategies for OC

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment





A patient with newly diagnosed advanced OC with a germline BRCA2 mutation has undergone debulking surgery and 6 cycles of carboplatin/paclitaxel and is about to start PARP inhibitor maintenance



## ADVANCES IN OVARIAN CANCER

### David O'Malley, MD

Professor Division Director, Gynecologic Oncology Co-Director, Gyn Oncology Phase I Program

### The James





#### Creating a cancer-free world. One person, one discovery at a time.



The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute




# PARPi in The First Line






# Integrated Maintenance Treatment Paradigm for Use in 1-L Ovarian Cancer <sup>(2022)</sup>




The James

#### PARP Inhibitors Yield Synthetic Lethality in Patients With HRD

- PARP inhibitors prevent repair of single-strand breaks, which accumulate and generate double-strand breaks
- People with HRD cannot repair double-strand breaks, which triggers cell death




#### SOLO-1: PHASE III TRIAL INVESTIGATING MAINTENANCE THERAPY WITH A PARP INHIBITOR IN NEWLY DIAGNOSED ADVANCED BRCA<sup>MUT</sup> OVARIAN CANCER



\*Upfront or interval attempt at optimal cytoreductive surgery for stage III disease and either biopsy and/or upfront or interval cytoreductive surgery for stage IV disease. BICR, blinded independent central review; ECOG, Eastern Cooperative Oncology Group; FACT-0, Functional Assessment of Cancer Therapy – Ovarian Cancer; FIGO, International Federation of Gynecology and Obstetrics; HRQoL, health-related quality of life; PFS, progression-free survival; PFS2, time to second progression or death; RECIST, Response Evaluation Criteria in Solid Tumours; TOI, Trial Outcome Index




#### SOLO-1 TFST substantially delayed by maintenance olaparib



Paul DiSilvestro, et al ESMO 2022

#### **PRIMA Trial Design**




1L, first-line; BICR, blinded independent central review; CR, complete response; OC, ovarian cancer; PFS2, progression-free survival 2; PR partial response; PRO, patient-reported outcomes; TFST, time to first subsequent therapy.

Modified from González-Martín A, Presented at ESMO 2019, Barcelona, Spain González-Martín A, et al. *N Engl J Med*. 2019. doi:10.1056/NEJMoa1910962.

The James

WEXNER MEDICAL CENTER

#### PRIMA Primary Endpoint, PFS Benefit in the HR-deficient Population




1L, first-line; CI, confidence interval; CT, chemotherapy; HR, homologous recombination; NE, not estimable; PD, progressive disease; PFS, progression-free survival. Sensitivity analysis of PFS by the investigator was similar to and supported the BICR analysis.

Modified from González-Martín A, Presented at ESMO 2019, Barcelona, Spain González-Martín A, et al. *N Engl J Med.* 2019. doi:10.1056/NEJMoa1910962.





#### PRIMA PFS Benefit in Biomarker Subgroups



#### Homologous Recombination Deficient (HRd)

- Niraparib provided similar clinical benefit in the HRd subgroups (*BRCA*mut and *BRCA*wt)
- Niraparib provide clinically significant benefit in the HR-proficient subgroup with a 32% risk reduction in progression or death

CI, confidence interval; HR, homologous recombination; mut, mutation; PFS, progression-free survival wt, wild-type.


Modified from González-Martín A, Presented at ESMO 2019, Barcelona, Spain González-Martín A, et al. *N Engl J Med*. 2019. doi:10.1056/NEJMoa1910962.



#### PRIMA/ENGOT-OV26/GOG-3012 Trial of Niraparib 1L Maintenance cont.

Final OS (62.5% maturity in overall population)

#### No difference in OS between niraparib and placebo arms in the overall, HRd, and HRp populations




- OS results for all prespecified biomarker-defined subgroups consistent with overall population<sup>c</sup>
- Assessment of long-term efficacy outcomes in high-risk aOC may be complicated by multiple factors<sup>1</sup>
  - Patient population<sup>2–4</sup>
  - Extended postprogression survival<sup>1,5</sup>
  - Subsequent therapy<sup>1,5</sup>

<sup>a</sup>Hazard ratios and 95% Cls for overall and HRd populations calculated using stratified Cox proportional hazards model with randomization stratification factors. <sup>b</sup>Hazard ratio and 95% Cl for HRp population calculated using unstratified Cox proportional hazards model. <sup>c</sup>OS results for the HRnd population (unstratified): hazard ratio (95% Cl), 1.39 (0.88–2.19). aOC, advanced ovarian cancer; HRd, homologous recombination deficient; HRnd, homologous recombination status not determined; HRp, homologous recombination proficient; OS, overall survival; Nir, niraparib; PBO, placebo. 1. Matulonis UA, et al. *Cancer.* 2015;121(11):1737–1746. 2. Siegel RL, et al. *CA Cancer J Clin.* 2024;74(1):12–49. 3. Elattar A, et al. *Cochrane Database Syst Rev.* 2011;201(8):CD007565. 4. Sun C, et al. *PLoS One.* 2014;9(5):e95285. 5. Delgado A, et al. *Am J Cancer Res.* 2021;11(4):1121–1131.

Phase III PAOLA-1/ENGOT-ov25: maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab as standard of care

Newly diagnosed FIGO stage III–IV high-grade serous/endometrioid ovarian, fallopian tube or primary peritoneal cancer\*




\*Patients with other epithelial non-mucinous ovarian cancer were eligible if they had a germline *BRCA1* and/or *BRCA2* mutation \*Bevacizumab: 15 mg/kg, every 3 weeks for a total of 15 months, including when administered with chemotherapy; \*By central labs; \*According to timing of surgery and NED/CR/PR BICR, blinded independent central review; HRQoL, health-related quality of life; PFS2, time to second progression or death; RECIST, Response Evaluation Criteria in Solid Tumours; TFST, time to first subsequent therapy or death; TSST, time to second subsequent therapy or death






#### **Updated PFS: HRD-positive population\***





\*Descriptive analysis; PFS by investigator-assessment (modified RECIST v1.1).

# Updated OS – First Line Ovarian Cancer



The James The Ohio State University WEXNER MEDICAL CENTER

# **Upfront Ovarian Cancer Maintenance Treatment**

- PARPi versus Bev versus Both
- Curative intent is the goal
- Biomarker derived therapy is now the standard.
- Management of Toxicity is essential



## **PARPi + IO in Ovarian Cancer**

Trial	Anti-angiogenic	PARPi	ICI	Median PFS	PFS HR
FIRST ENGOT OV-44	<u>+</u> Bevacizumab	Niraparib	Dostarlimab	Statistically signific (press re	-
DUO-O ENGOT OV-46	Bevacizumab	Olaparib	Durvalumab	25.1 mo (ITT population)	0.61 (0.51-0.73)
ATHENA GOG-3020 ENGOT OV-45	-	Rucaparib	Nivolumab	15.0 mo (ITT population)	1.29 (1.08–1.53)
ENGOT OV-43 KEYLYNK-001	<u>+</u> Bevacizumab	Olaparib	Pembrolizumab	23.9 mo (CPS $\geq$ 10 population)	0.66 (0.53-0.83)



Monk et al. ESMO 2024; Abstract LBA30.

Vergote et al. ESGO 2025.

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-trial-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer/



#### **Recurrent Serous Carcinoma of the Ovary, Stage IIIC** BRCA1+, PD-L1+, FOLR1 negative (0%), Her2 negative (score=0)

Diagnosed in 2006 - TAH/BSO/LND/Omentectomy/Extensive TRS - Stage IIIC Ovarian Cancer

- Followed by Taxol/Carbo x 6 cycles
- Recurred approximately 36 months later with GI symptoms (N/V with GERD), abdominal distention, elevated CA-125 (60)
- Underwent TRS/Omentectomy/Splenectomy positive for metastatic serous carcinoma
  - Followed by Carbo/Gem/Bev x 6 cycles
- Diagnosed with recurrence 13 years later
  - Followed by Gem/Carboplatin/Bev
  - Started maintenance Bev
  - Started Olaparib, discontinued after 1 dose due to allergic reaction
  - Switched to Niraparib Cycle 2
  - Completed 5 cycles of maintenance Bev, discontinued Cycle 6 due to persistent hypertension.
  - Continued Niraparib

# **Roundtable Discussion**



#### **CONSIDERATIONS FOR PATIENTS RECEIVING A PARP INHIBITOR**

Courtney Arn, CNP The Ohio State University James Comprehensive Cancer Center Columbus, Ohio

#### INITIATION OF PARP INHIBITORS

- Baseline Labs
- Patient Education:
  - MOA
  - Indication
  - Side effects/expectations
  - Treatment Plan/Schedule
- Supportive Care
- Co-pay Evaluation/Financial Support

#### **MECHANISM OF ACTION**

- PARP inhibitors block the activity of PARP enzymes, disrupting the normal DNA repair process and ultimately causing cell death, particularly in cancer cells with impaired DNA repair mechanisms like BRCA mutations.
- Tumor cells carrying a BRCA mutation have been shown to be significantly more sensitive to PARP inhibition than tumors that do not carry a BRCA mutation

#### SIDE EFFECTS - NIRAPARIB

- Thrombocytopenia (66%)
- Anemia (64%)
- Nausea (57%)
- Fatigue (51%)
- Neutropenia (42%)
- Constipation (40%)
- Musculoskeletal pain (39%)
- Hypertension (18%)
- Warnings & Precautions: MDS/AML, Hematologic, Hypertension, PRES, Embryo-Fetal Toxicity

#### SIDE EFFECTS – OLAPARIB

- Nausea (77%)
- Fatigue (67%)
- Abdominal pain (45%)
- Vomiting (40%)
- Anemia (38%)
- Diarrhea (37%)
- Warnings & Precautions: MDS/AML, Pneumonitis, VTE, Embryo-Fetal Toxicity

## MONITORING & MANAGING SIDE EFFECTS

- Nausea: Prophylactic anti-emetics 30-60 minutes prior to dosing and PRN
- Constipation: Stool softeners, Laxatives, Diet, Physical Activity
- Diarrhea: Anti-diarrheal, Diet, Fluids, Electrolytes
- Fatigue: Hydration, Exercise, PT, consider stimulants
- Hematologic: Plan for monitoring labs, transfuse as needed

#### GRADE ≥3 AES OF INTEREST

	PRIMA		PAOLA-1		SOLO-1	
	Niraparib	Placebo	Bevacizumab + Olaparib	Bevacizumab + Placebo	Olaparib	Placebo
n	484	244	535	267	260	130
Anemia	31%	2%	17%	<1%	22%	2%
Neutropenia	13%	١%	6%	3%	9%	5%
Thrombocytopeni a	29%	<1%	2%	<1%	١%	2%
Fatigue	2%	1%	5%	١%	4%	2%
MDS/AML	Not reported	Not reported	١%	<1%	١%	0
Nausea	1%	١%	2%	١%	١%	0%
Vomiting	1%	1%	١%	2%	<1%	١%
Diarrhea	1%	*****	2%	2%	3%	0
Constipation	<1%	0	Not Reported	Not Reported	0	0
Hypertension	6%	۱%	I 9%	30%	Not Reported	Not Reported

Cross-trial comparisons are not head-to-head studies; varying study designs, methodology, and populations limit ability to draw conclusions of comparative efficacy and safety.

AE, adverse event; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; thrombo, thrombocytopenia;  $\downarrow$ plt, decreased platelets.

I. González-Martín A, et al. N Engl J Med. 2019. doi:10.1056/NEJMoa1910962. 2. González-Martín A, et al. Presented at: ESMO Congress; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA1.

3. Ray-Coquard IL, et al. Presented at: ESMO Congress; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA2. 4. Moore K, et al. N Engl J Med. 2018;27;379(26):2495-2505.

#### AML/MDS WITH PARP INHIBITOR TREATMENT

Trial	Placebo	Parp Inhibitor
SOLO-2 Olaparib	4%	8%
NOVA Niraparib	I.7% (3.1% in BRCA)	3.5% (6.6% in BRCA)
ARIEL3 Rucaparib	3.2	3.8

Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and *BRCA1/2* mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Supplementary appendix [published online March 18, 2021]. *Lancet Oncol.* Matulonis UA, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase 3 trial of niraparib in recurrent ovarian cancer. Presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women's Cancer; March 19-21, 2021; Virtual. Abstract 37 Coleman et al. Overall Survival Results From ARIEL3: A Phase 3 Randomized, Double-blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma. IGCS 2022

#### AML/MDS WITH PARP INHIBITOR TREATMENT

Trial	Placebo	Parp Inhibitor
SOLO-I Olaparib	0.8%	I.5%
PRIMA Niraparib	1.6%	2.3%
PAOLA-I Olaparib + bevacizumab	2.2%	1.7%

DiSilvestro P et al. J Clin Oncol 2022;41(3):609-17; Monk BJ et al. Ann Oncol 2024;35(11):981-92; Ray-Coquard I et al. Ann Oncol 2023;34(8):681-92.

#### **DOSING & ADMINISTRATION**

	Olaparib	Niraparib
Dosage Forms	Tablets: 100 mg or 150 mg	Tablets: 100 mg
Dose	300 mg bid	300 mg daily
Starting Dose Modifications	Moderate renal impairment CYP3A inhibitor use	If baseline weight: <77 kg OR platelets: <150,000/uL
Monitor	CBC at baseline and monthly thereafter	<ul> <li>CBC weekly for the first month, then monthly for the next 11 months, and then periodically</li> <li>BP monthly during the first year and</li> </ul>
		<ul> <li>BP monthly during the first year and periodically</li> </ul>

#### NIRAPARIB INDIVIDUALIZED STARTING DOSE



Niraparib prescribing information. Accessed 4/2025.

# DOSE MODIFICATION

	PRIMA		PAOLA-1		SOLO-1	
	Niraparib	Placebo	Bevaci- zumab + Olaparib	Bevaci- zumab + Placebo	Olaparib	Placebo
n	484	244	535	267	260	130
Dose reduction	71%	8%	41%	7%	28%	3%
Dose interruption	80%	18%	54%	24%	52%	17%
AE leading to discontinuation	12%	3%	20%	6%	12%	2%
Grade >/= 3 AEs	71%	19%	57%	51%	39%	18%

AE, adverse event.

1. González-Martín A, et al. N Engl J Med. 2019. doi:10.1056/NEJMoa1910962. 2. González-Martín A, et al. Presented at: ESMO Congress; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA1. 3. Ray-Coquard IL, et al. Presented at: ESMO Congress; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA2. 4. Moore K, et al. N Engl J Med. 2018;27;379(26):2495-2505.

# **Roundtable Discussion**



## Agenda

**Introduction:** Overview of Ovarian Cancer (OC) Management

**Module 1:** Genetic Testing for Newly Diagnosed Advanced OC

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

Module 3: Other Available and Investigational Novel Strategies for OC

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment



# **Clinical Scenario**

A patient with advanced OC undergoes resection, receives adjuvant carboplatin/paclitaxel and PARP inhibitor maintenance, experiences disease progression and then receives 2 subsequent lines of platinumbased chemotherapy. Her disease is now platinum resistant and is found to be HER2-positive, and she is about to start treatment with trastuzumab deruxtecan (T-DXd).



**Targeted (ADCs) Therapy - Ovarian Cancer** 


David M O'Malley, MD The Ohio State University and The James Comprehensive Cancer Center Columbus, Ohio



#### **Trastuzumab Deruxtecan**

#### HER2-directed mAb<sup>1</sup>

- Provides targeted delivery of cytotoxic agent<sup>1,2</sup>
- Consists of the same amino acid sequence as trastuzumab<sup>3</sup>



#### Topoisomerase l inhibitor payload<sup>1,2,a</sup>

- Highly potent payload is an exatecan derivative, known as DXd, with a short systemic halflife<sup>1,3</sup>
- Upon release, membranepermeable payload causes DNA damage and cell death, resulting in destruction of targeted tumor cells and neighboring cells present in the tumor microenvironment, known as the bystander antitumor effect<sup>1,3,4</sup>

# Tumor-selective cleavable linker<sup>1-3,a</sup>

- Attaches payload to the antibody<sup>1</sup>
- Linker-payload is stable in plasma<sup>2,3</sup>
- Linker selectively cleaved by enzymes that are upregulated in tumor cells<sup>1,3</sup>

1. Prescribing information. 2025.

2. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. *Clin Cancer Res.* 2016;22(20):5097-5108.


3. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. *Chem Pharm Bull (Tokyo).* 2019;67(3):173-185.

<sup>a</sup>Based on in vitro and in vivo non-clinical studies. The clinical relevance of these features is under investigation.

https://www.enhertuhcp.com/en/mechanism-of-action. accessed on 4/6/25

# What Is the Incidence of HER2 Expression Across Solid Tumors?

#### **Distribution of HER2 IHC expression levels across cancers**




CCA = cholangiocarcinoma; CNS, central nervous system; CUP = cancer of unknown primary; FT = fallopian tube cancer; GEJ = gastroesophageal; GI = gastrointestinal; HCC = hepatocellular carcinoma; HER2 = human epidermal growth factor receptor 2; HN = head and neck; HN-ACC = head and neck-adenoid cystic carcinoma; HNSCC = head and neck squamous cell carcinoma; IHC = immunohistochemistry. \*Row percentages were used in the construction of this table.

#### Uzunparmak B et al. Ann Oncol 2023;34:1035-46.

#### **HER2** expression across solid tumors

			Distribution of HER2 IHC scores across cancers						
			HER2 IHC expression levels, %						
	Cancer types		0	1+	2+	3+	Total, n		
	Breast Gastric/GEJ		43 51	28 21	19 14	10 14	2611 208		
1	Biliary tract	CCA Gallbladder Ampullary	55 46 50	29 21 33	12 24 17	4 9 0	122 33 6		
	GI—lower	Colorectal Appendiceal Small bowel Anal	68 78 78 100	21 16 4 0	8 6 9 0	3 0 9 0	577 50 23 5		
	Gl—other	Pancreas HCC Mixed CCA and HCC	67 56 67	24 19 33	8 25 0	2 0 0	67 32 6		
(	Gynecological	Endometrial Ovarian/FT Peritoneal Cervical Vaginal Vulvar	41 62 71 64 100 29	8 13 29 7 0 14	39 20 0 14 0 43	13 5 0 14 0 14	127 85 14 14 2 7		
	Head and neck	HN-ACC HN-Other HN-salivary gland HNSCC	90 54 38 70	0 23 30 17	10 15 21 4	0 8 13 9	10 13 48 23		
	Genitourinary	Urothelial Prostate Renal cell Germ cell/testicular Penile	32 87 95 100 100	18 13 5 0 0	28 0 0 0 0 0	21 0 0 0 0	176 31 19 3 1		
-	Thoracic	Lung Thymic	50 100	32 0	15 0	3 0	211 4		
:	Skin	Melanoma Non-melanoma skin	100 71	0 14	0 14	0 0	14 7		
ſ	Other	Adrenal CUP CNS Sarcoma Thyroid	67 54 50 95 96	0 28 50 3 4	33 15 0 3 0	0 4 0 0 0	3 54 2 37 56		
	Total		2361 (50)	1137 (24)	796 (17)	407 (9)	4701		


#### **Does It Change With the Tissue Tested** (primary vs metastatic breast cancer)?



		HE			
		HER2–	HER2-low	HER2+	Total
HER2 primary <i>n</i> , %	HER2–	157 (65.4)	78 (32.5)	5 (2.1)	240
	HER2-low	96 (34.8)	171 (62.0)	9 (3.3)	276
	HER2+	4 (3.5)	14 (12.4)	95 (84.1)	113
Total		257 (40.9)	263 (41.8)	109 (17.3)	629

Uzunparmak B et al. Ann Oncol 2023;34:1035-46.

#### **Across Time?**



		HE				
		HER2 0	HER2 1+	HER2 2+	HER2 3+	Total
HER2	HER2 0	26 (57.8)	9 (20.0)	10 (22.2)	0 (0)	45
first	HER2 1+	14 (32.6)	13 (30.2)	15 (34.9)	1 (2.3)	43
biopsy	HER2 2+	5 (19.2)	6 (23.1)	14 (53.8)	1 (3.8)	26
<i>n</i> , %	HER2 3+	1 (10.0)	2 (20.0)	0 (0)	7 (70.0)	10
Total		46 (37.1)	30 (24.2)	39 (31.5)	9 (7.3)	124

Original Reports | Gynecologic Cancer


# In the DESTINY-PanTumorO2 Phase II Trial In the DESTINY-PanTumorO2 Phase II Trial

Funda Meric-Bernstam, MD<sup>1</sup> (D); Vicky Makker, MD<sup>2,3</sup> (D); Ana Oaknin, MD<sup>4</sup> (D); Do-Youn Oh, MD<sup>5</sup> (D); Susana Banerjee, PhD<sup>6</sup> (D); Antonio González-Martín, MD<sup>7</sup> (D); Kyung Hae Jung, MD<sup>8</sup> (D); Iwona Ługowska, MD<sup>9</sup>; Luis Manso, MD<sup>10</sup> (D); Aránzazu Manzano, MD<sup>11</sup>; Bohuslav Melichar, MD<sup>12</sup>; Salvatore Siena, MD<sup>13</sup> (D); Daniil Stroyakovskiy, MD<sup>14</sup> (D); Anitra Fielding, MBChB<sup>15</sup>; Yan Ma, MSc<sup>16</sup>; Soham Puvvada, MD<sup>15</sup>; Norah Shire, PhD<sup>15</sup>; and Jung-Yun Lee, MD<sup>17</sup> (D)

J Clin Oncol 2024;42(1):47-58.



#### DESTINY-PanTumor02: Phase II Trial of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors





Meric-Bernstam F et al. J Clin Oncol 2024;42(1):47-58.

#### DESTINY-PanTumor02 Response by HER2 Expression Level (central)




RTP RESEARCH TO PRACTICE


GYN = gynecological; NE = not estimable; NR = not reached.


Lee J-Y, et al. International Gynecological Cancer Society (IGCS) 2023.

### GOG 3112/ENGOT-ov89 Phase 3 DESTINY-Ovarian01: T-DXd + Bevacizumab as 1L Maintenance Therapy in HER2-Expressing Ovarian Cancer



### **Targeting CDH6**





ayload	Topoisomerase 1 inhibitor (DXd	
DAR	8	
Linker	Cleavable tetrapeptide based linker	
Trial	NCT04707248	

#### Median DOR:a

Ρ

11.2 months (95% CI: 3.1–NE) Median (range) FU: 6.7 months (1.4–16.8)

Median TTR:ª

5.7 weeks (95% CI: 5.3-11.4)


#### Median PFS:b

8.1 months (95% CI: 5.3–NE) Median (range) FU: 4.0 months (0–25.1)

1. Moore K, et al. Presented at European Society for Medical Oncology (ESMO) Annual Meeting; 20-24 October 2023; Madrid, Spain.;

2. NCT04707248. Accessed from: https://clinicaltrials.gov/study/NCT04707248?cond=NCT04707248&rank=1.

### REJOICE-Ovarian01/GOG-3096: Phase 2/3 Randomized Study of R-DXd in Platinum-Resistant EOC



#### NCT06161025

### **Key Takeaways**

- Phase 2 DESTINY-PanTumor02, led to tumor-agnostic indication
  - April 5, 2024: FDA granted accelerated approval to T-DXd for unresectable/HER2+ (IHC3+) solid tumors after prior systemic treatment and no satisfactory alternative treatment options
  - Greatest benefit in IHC 3+ population
- Further exploration of T-DXd in HER2 IHC 1+/HER2-low is warranted
- Multiple Trials are being initiated for HER2 expressing gyn cancer
- Next Generation of ADCs is here




#### **Recurrent Endometrioid Ovarian Cancer**


Line of therapy	Therapy
1	Tumor Reductive Surgery + Carboplatin/paclitaxel x 6
2	Carboplatin/paclitaxel x 6
3	PD1i x 5 years
4	Megestrol
5	Letrozole + ribociclib

- NGS Testing
  - PTEN Mutation
- HER2 IHC: 3+
- Folate Receptor alpha: 0%
- Started T-DXd
- Reduced dose to 4.4 mg/kg Cycle 3 due to significant fatigue and diarrhea
- Reduced dose to 3.2 mg/kg Cycle 9 due to persistent fatigue despite supportive care.
- Has Received >20 cycles

#### Baseline



#### After 20 cycles — ongoing PR



### **Roundtable Discussion**



### Nursing Considerations for Patients Receiving T-DXd

Courtney Arn, CNP The Ohio State University James Comprehensive Cancer Center Columbus, Ohio

### Patient Education

- MOA/Indication
- Potential Side Effects
- Symptom Management
- Treatment Plan/Schedule
- Pre and post medications
- Baseline labs and procedures (echo)

### How does T-DXd work?

HER2-directed mAb

•Provides targeted delivery of cytotoxic agent

•Consists of the same amino acid sequence as trastuzumab Topoisomerase I inhibitor payload

•Highly potent payload is an exatecan derivative, known as DXd

•Upon release, payload causes DNA damage and cell death, resulting in destruction of targeted tumor cells and neighboring cells present in the tumor microenvironment, known as the bystander antitumor effect

### Tumor-selective cleavable linker

•Attaches payload to the antibody

Trastuzumab deruxtecan prescribing information, accessed 4/2025.

### Side Effects

- Nausea (72%)
- Fatigue (55%)
- Vomiting (38%)
- Alopecia (37%)
- Constipation (32%)
- Decreased appetite (31%)
- Diarrhea (30%)
- Musculoskeletal pain (24%).
- Hematologic: Leukopenia (73%), Anemia (67%), Neutropenia (65%), decreased lymphocyte count (60%), Thrombocytopenia (48%), increased AST (46%), increased ALT (44%), increased alkaline phosphatase (39%), Hypokalemia (32%)

Trastuzumab deruxtecan prescribing information; accessed 4/2025

### ILD/Pneumonitis Associated With T-DXd

- 15% of patients receiving T-DXd
- 87.0% had their first event within 12 months
  - Median: 5.4 months
  - Range: <0.1–46.8 months</p>
- Median time to onset: 5-6 months
- Most patients with ILD/pneumonitis experienced low-grade events (grade 1 or 2, 77.4%)
- Overall rate of fatal events: 2.2%

### Five "S" strategies to help detect and manage ILD/pneumonitis

Screen	Scan	Synergy	Suspend treatment	Steroids
<ul> <li>Careful patient selection</li> <li>Optimize the monitoring strategies based on the baseline risk;</li> <li>Screening continues during treatment</li> <li>Regular clinical assessments to exclude signs/symptoms of ILD</li> <li>Increased knowledge on the impact of prior ILD with other treatments on future risk of ILD</li> </ul>	<ul> <li>The fundamental diagnostic tools for ILD remain CT scans (high-resolution)</li> <li>Baseline scan is recommended</li> <li>Repeat scans to be performed every 6 to 12 weeks</li> </ul>	<ul> <li>Involves a teamwork</li> <li>Educating patients</li> <li>Educate the entire the care team</li> <li>Multidisciplinary management once ILD is suspected <ul> <li>Pulmonologists</li> <li>Additional Testing</li> </ul> </li> </ul>	<ul> <li>T-DXd should always be interrupted if ILD is suspected</li> <li>Should only be restarted in the case of asymptomatic ILD that fully resolves</li> </ul>	<ul> <li>Mainstay for treating are corticosteroids</li> <li>Dose to be adapted to the toxicity grade</li> </ul>

Tarantino P, Tolaney SM. J Oncol Practice. Trastuzumab deruxtecan prescribing information. Accessed 4/2025.

### Interstitial Lung Disease: Recognition and Management

- Advise patients of risks of ILD prior to start of treatment, as well as signs/symptoms of ILD
- Monitor for new or worsening cough, dyspnea, or fever
- Incidental findings on routine scan
- Symptomatic findings

#### If ILD is suspected...

- Exclude other etiologies, including infectious etiologies
- Initiate evaluation without delay, which may include
  - CT (High-resolution)
  - Consultation with pulmonologist
  - Infectious Workup
  - Additional tests, as clinically indicated

#### Grade 1 (asymptomatic)

- Hold T-DXd until resolved
- May resume treatment once fully resolved by imaging
- Consider starting systemic steroids (eg, 0.5 mg/kg/day of prednisone or equivalent) until improvement, followed by gradual taper over 4 weeks
- If >28 days to resolve, reduce dose by 1 dose level

#### Grade 2+ (symptomatic)

- Discontinue T-DXd permanently
- Begin steroid treatment (eg, prednisone ≥1 mg/kg daily) with gradual taper

Trastuzumab deruxtecan prescribing information, Accessed 11/8/2024. Swain SM, et al. Cancer Treat Rev. 2022;106:102378.

#### Anemia/Neutropenia/Thrombocytopenia

- Dose reductions or delays
- Transfusion
- G-CSF for prevention and/or management of neutropenia

#### Nausea/Vomiting

- Moderate-High emetogenic risk
- Initiate tailored prophylactic antiemetic regimens (2–3 agents) before T-DXd infusion + home regimen for 3-4 days

#### Fatigue

- Assess/counsel
- Consider holding/dose reductions
- Rule out other causes
- Encourage exercise/physical activity/PT

#### Left ventricular dysfunction

- Baseline LVEF and regular monitoring (every 3–4 months)
- Dose delay/discontinuations

#### Diarrhea

- Infectious workup
- Anti-diarrheal (Loperamide, Diphenoxylate / Atropine)
- Fluids/electrolytes

#### Alopecia

- Patient counseling/education
- Wig prescription
- Scalp cooling



#### Continue until disease progression or unacceptable toxicity

Trastuzumab deruxtecan official website. Accessed 4/2025.

### **Recommended Dose Reductions**

Dose Reduction Schedule	5.4 mg/kg starting dose	
First Dose Reduction	4.4 mg/kg	
Second Dose Reduction	3.2 mg/kg	
Requirement for further dose reduction	Discontinue Treatment	

Trastuzumab deruxtecan prescribing information. Accessed 4/2025.

### **T-DXd: Infusion-Related Reactions**

- Prompt recognition and treatment are important for reducing the risk of severe symptoms
  - Signs of T-DXd-related IRRs include fever and chills, N/V, pain, headache, dizziness, dyspnea, and/or hypotension
- Infusion 1 over 90 minutes → if well tolerated → subsequent infusions 30 minutes
  - 1% to 3% of patients receiving T-DXd experience an IRR with T-DXd 5.4 mg/kg.
- Grade 1: Reduce infusion rate to 50%
- Grade 2: Temporarily stop infusion
- Grade 3 or 4: Permanently stop

- Keep resources to treat IRR readily on hand
- Suspected anaphylaxis:
  - Follow local management guidelines
  - epinephrine (1 mg/mL IM every 5-15 minutes);
  - normal saline (1-2 L at 5-10 ml/kg for first 5 minutes IV);
  - H1/H2 antagonists

IRR = infusion-related reaction; N/V = nausea and/or vomiting.

Rugo HS, et al. ESMO Open. 2022;7:100553. Trastuzumab deruxtecan prescribing information.

### CASE STUDY

- Patient with recurrent high grade serous ovarian cancer (germline BRCA2+, HER2 IHC 3+, FOLR 0%)
- 2020: Diagnosed
- 2022: Completed adjuvant carboplatin and paclitaxel, followed by PARP maintenance
- 2023: Disease recurrence; Gem/Cis/Bev followed by maintenance Bev x 9 months
- 2024: Disease progression; Gem/Cis/Bev, progressed after 3 cycles of maintenance Bev
- 2025: Started treatment on trastuzumab deruxtecan (T-DXd).
- Near CR after 3 cycles, side effects are well controlled with supportive care
- Social History: 2 children in high school, enjoys traveling

### **Roundtable Discussion**



### Other Nursing Considerations Related to OC Management

Jennifer Filipi, MSN, NP

Department of Gynecologic Oncology Massachusetts General Hospital Cancer Center Boston, Massachusetts

### **Case Presentation**

- 39 year old therapist, artist, and traveler with platinum resistant ovarian cancer, negative genetics, FOLR1 negative, HER2 negative.
- Diagnosed in 2020, Stage III
  - Complete cytoreductive surgery  $\rightarrow$  Carbo/paclitaxel
  - 2022: Carbo/PLD
  - 2023: platinum resistant  $\rightarrow$  bev/paclitaxel
  - 2023: clinical trial (ID + immunotherapy)





### **Clinical Trial Participation**

- Advantages: good potential for an active drug (several FDA approvals in last 5-10 years), clinical trial team, opportunity to contribute to the fight
- Barriers: frequency of visits, live far from hospital (not available at satellite sites), eligibility requirements often strict
- Communication: detailed explanations (don't just assume), "I don't want to be a guinea pig"- no placebos, will not affect overall care, clinical trial support from pharma company

### Optimizing Oncology Nursing Care

- Patient education and support
  - Discuss goals of care with patient, what is important now, may change over time
    - Introduce palliative care early
  - Educate patients on disease and its management
    - Including potential treatment-related adverse events
  - Provide access to support and resources: support groups, social work, lifestyle medicine, nutrition
  - Encourage ALL patients to participate in clinical trials, if available at your work site
  - Be mindful of social and financial burdens, including oral adherence
  - Helpful tips: bring a support person, give handouts for reference back, "never worry alone" motto
- Multidisciplinary approach



# Back to our case...

Patient in a PR (over a year on trial)

TURNING THE TIDE OVARIAN CANCER RETREAT

**June 15 - 19, 2025** Medomak Retreat Center Washington, Maine

A retreat to empower women om New England who are living with ovarian cancer



### **Roundtable Discussion**



### Agenda

**Introduction:** Overview of Ovarian Cancer (OC) Management

**Module 1:** Genetic Testing for Newly Diagnosed Advanced OC

Module 2: Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC

**Module 3:** Other Available and Investigational Novel Strategies for OC

Module 4: Current and Future Role of Mirvetuximab Soravtansine in OC Treatment



### **Clinical Scenario**

A patient with advanced OC undergoes resection, receives adjuvant carboplatin/paclitaxel and PARP inhibitor maintenance, experiences disease progression and then receives 2 subsequent lines of platinumbased chemotherapy. Her disease is now platinum resistant and has high FR $\alpha$  expression, and she is about to start treatment with mirvetuximab soravtansine.



### **Current and Potential Future Role of Mirvetuximab Soravtansine in Ovarian Cancer Treatment**

Shannon N. Westin, MD, MPH


Professor

Department of Gynecologic Oncology and Reproductive Medicine

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center

Making Cancer History®

### **Typical Course of Advanced Ovarian Cancer**



Ledermann JA, et al. Ann Oncol. 2013, Pignata S, et al. Ann Oncol. 2017; du Bois A, et al. Cancer 2009, Wilson MK, et al. Ann Oncol. 2017

### **Targeting Folate Receptor Alpha**

- FRα is a cell surface folate receptor which mediates folate transport into epithelial cells.
- FRα expression is limited on normal cells, but is upregulated on cancers, primarily ovarian, but also endometrial, and triple negative breast
- FRα may be expressed on the alveoli of the lungs and on renal proximal tubules. However, these receptors are located on the surface of the cell facing the alveolar and tubular lumen, which reduces the exposure of the targets to circulating anti-folate agents
- Expression in ovarian cancer varies by histology (80-90%)
- 76% HGS
- 50% LGS
- 32% clear cell
- Association with prognosis has been mixed


Kobel et al. Br. J Cancer (111); 2014; Moore KN et al. ESMO. 2019; Oaknin A et al. ASCO 2023; Chen YL, et al. *Mol Oncol* 2012

### **PS2+ Scoring**

Determined by staining intensity and percentage of tumor cells staining at 0, 1+, 2+, or 3+

1+ intensity 2+ intensity


3+ intensity



PS2+ Scoring Positive: ≥ 50% tumor cells with ≥ 2+ FRα membrane staining.

# Mirvetuximab soravtansine, first FRα-targeted ADC approved for PROC

Antibody-drug conjugate (ADC) comprising an FRα-binding antibody, cleavable



#### Key eligibility criteria

- Platinum-resistant ovarian cancer
- Prior bevacizumab required, prior PARPi allowed
- 1–3 prior lines of therapy
- Patients with *BRCA* mutations allowed
- FRα-positive (≥75% of cells staining positive with ≥2+ staining intensity)

Mirvetuximab soravtansine (N=106) 6.0 mg/kg adjusted ideal body weight (AIBW) q3w

linker, and a maytansinoid DM4 payload


#### **Primary endpoint**

• ORR per Investigator

**SORAYA (NCT04296890)** 

#### Secondary endpoints

• DOR, PFS, OS, CA-125 response by GCIG criteria, safety




FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

f Share 🦉 Tweet in Linkedin 🖾 Email 🖨 Print


On November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha (FR $\alpha$ ) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Mirvetuximab soravtansine-gynx is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. Patients are selected for therapy based on an FDA-approved test.

#### Moore KN et al. Cancer. 2017; Matulonis UA et al. J Clin Oncol. 2023

## MIRASOL (NCT04209855): Randomized, phase 3 study of MIRV vs chemotherapy in FRα-high platinum–resistant ovarian cancer



### **Confirmation of Superiority – OS Benefit!!!!**



Moore et al. NEJM 2023

# PICCOLO: Mirvetuximab soravtansine in platinum sensitive ovarian cancer


Characteristics	N=79					
Age, median (range), years	66 (41-84)					
Race, n (%)						
White	65 (82.3) 4 (5.1)					
Black or African American						
Asian	1 (1.3)					
# prior lines of systemic therapy, n (%)						
1-2 <sup>a</sup>	49 (62.0)					
≥3	30 (37.9)					
Prior exposure to taxanes, n (%), Yes	77 (97.5)					
Exposed in multiple lines	20 (25.3)					
Prior exposure to PARPi <sup>b</sup> ,n (%), Yes	64 (81.0)					
Progression on PARPi <sup>c</sup>	59 (74.7)					
Prior exposure to bev, n (%), Yes	51 (64.6)					
Most recent PFI (months) <sup>d</sup> , n (%)						
≤12	43 (54.4)					
>12	34 (43.0)					

Percentage change from baseline 80 Maximum Tumor % Change From Baseline 60<sup>.</sup> 40 20 -20 -40 -60 -80 100-**Primary Endpoint** N=79 **ORR**, n (%) 41 (51.9) 10 1-63 3 05% CI

95% CI	40.4-03.3
Best Response, n (%)	
CR	6 (7.6)
PR	35 (44.3)
SD	29 (36.7)
PD	7 (8.9)
Not evaluable	2 (2.5)


n=41
8.25 (5.6-10.8)
N=79
6.93 (5.8-9.6)

Alvarez Secord; Ann Oncol 2025



Alvarez Secord; Ann Oncol 2025

#### GOG-3078/IMGN853-0421/GLORIOSA Randomized Phase 3 Trial for Mirvetuximab + Bevacizumab Maintenance in FRα-high Platinum Sensitive Ovarian Cancer



Triplet treatment consists of platinum+chemotherapy+bevacizumab for planned 6 cycles (minimum 4 and maximum 8 cycles), including at least 3 cycles of bevacizumab for planned 6 cycles of bevacizumab to restrict a be betreated and followed while on their run-in triplet therapy must sign a run-in consent as part of the main consent form if they meet eligibility oriteria as assessed by the investigator. Maintenance treatment must begin s12 weeks from last dose of triplet therapy and within 30 days of randomization. Treatment consist, death, or sponsor study termination. AIBW, also known as AdjBW, is calculated as IBW (kg) + 0.4 (actual weight – IBW). IBW for females is calculated as 0.9\*height (cm) – 92.



PARTNERS

NCT05445778

#### Key Eligibility Criteria:

- Platinum-sensitive HGS ovarian cancer
- 1 prior platinum treatment
- Prior PARPi required if BRCA+
- CR, PR, or SD after treatment with platinum-based doublet
- + bevacizumab required

### **Roundtable Discussion**




### Nursing Considerations for Patients Receiving Mirvetuximab Soravtansine

Jennifer Filipi, MSN, NP

Department of Gynecologic Oncology Massachusetts General Hospital Cancer Center Boston, Massachusetts 64-year-old new grandmother with platinum resistant ovarian cancer


- Diagnosed in 2019
- Negative genetics
- C/T and cytoreductive surgery
- Recurrence in 2021: C/PLD
- Recurrence in 2023: C/Gem/Bev

• Jan 2025: recurrence c/b rectal bleeding, hydronephrosis, significant pain



# Molecular testing


- Snapshot (in house molecular testing) with no actionable mutations
- HER2 negative (0)
- FOLR1 +





# Mirvetuximab

- Antibody drug conjugate
  - 3 components
    - Antibody, linker, cytotoxic payload



- Approved for platinum resistant ovarian cancer
- + expression = 75% or greater


- Targets folate receptor 1 (FOLR1) on surface of cancer cells
  - Often present in ov ca cells; limited expression in normal cells
- Bystander effect

# Mirvetuximab: Common Side Effects

- Eye disorders: Blurry vision, dry eyes, eye irritation, eye redness
- Low blood cell counts
- Fatigue
- Nausea, vomiting
  - Most common on the day(s) of chemotherapy and for 2-3 days afterwards
- Diarrhea, constipation
- Liver enzyme elevations
- Peripheral neuropathy:
  - Numbness, tingling ("pins and needles"), or burning sensations in the hands and/or feet
    - If you already have neuropathy when you start this treatment, it may get worse

# Mirvetuximab: Rare but Serious Side Effects

- Infusion related/hypersensitivity reactions
  - This reaction is most common with the first infusion and the risk for it after the first infusion significantly declines
- Inflammation of the lungs
  - If you experience unexplainable symptoms consisting of but not limited to dry cough, shortness of breath, or difficulty breathing then report it to your oncologist



# Eye Care During Treatment

- To decrease risk of visual complications, you will be required to:
  - Have an eye examination (visual acuity and slit lamp) done prior to your first infusion
  - Have follow-up eye exams before **every other dose** of mirvetuximab soravtansine during the first 8 treatment cycles, then as directed by your provider
  - Administer preservative free artificial tears in each eye at least four times a day, starting with the first treatment and continuing until the end of treatment
  - Administer corticosteroid eye drops in each eye starting the day prior to and on days 1 to 8 of each treatment cycle, starting with the first cycle and continuing until the end of treatment
  - Avoid the use of contact lenses
  - Use caution when driving or operating heavy machinery
  - Wear sunglasses when outdoors because your eyes may become more sensitive to sunlight during treatment with mirvetuximab soravtansine
  - If you experience eye toxicity, your oncologist may hold (temporarily stop) this medication until your condition improves

#### Home medications

• **Corticosteroid eye drops**: Instill the number of drops shown below starting the **day prior** to each treatment cycle and continue use for only the first **eight days** of each treatment cycle

Treatment Day	-1	1	2	3	4	5	6	7	8
Number of eye drops per eye per day		Six			Four				

• Artificial tears (preservative free): Instill 1 drop into each eye (waiting at least 10 minutes after administration of dexamethasone eye drops) four times a day during the treatment period

#### Back to our case...

- 3 cycles later, complete resolution of rectal bleeding and pain
- CA125 decreasing
- Mild blurred vision with changes on eye exam.
  - Management: ophthalmologist visit, held x1 week
  - Lower dose by one dose level
- Eye toxicity resolved
- Continues to tolerate well



### **Roundtable Discussion**



#### Understanding the Current Paradigm and New Approaches in the Care of Patients with Cancer

A Complimentary NCPD Hybrid Symposium Series Held During the 50<sup>th</sup> Annual ONS Congress

**Pancreatic Cancer Friday, April 11, 2025** 6:00 PM - 7:30 PM Faculty Farshid Dayyani, MD, PhD **Caroline Kuhlman, MSN, APRN-BC** Philip A Philip, MD, PhD Amanda K Wagner, APRN-CNP, AOCNP

> Moderator Neil Love, MD



Thank you for joining us! Please take a moment to complete the survey currently up on Zoom. Your feedback is very important to us. The survey will remain open up to 5 minutes after the meeting ends.

To Claim NCPD Credit In-person attendees: Please refer to the program syllabus for the NCPD credit link or QR code.

Virtual attendees: The NCPD credit link is posted in the chat room.

NCPD/ONCC credit information will be emailed to each participant within 1 to 2 business days.

